Literature DB >> 7662126

Prophylactic anti-lipopolysaccharide freeze-dried plasma in major burns: a double blind controlled trial.

E B Jones1.   

Abstract

A double-blind controlled trial to test the efficacy of freeze-dried plasma containing a high titre of anti-lipopolysaccharide (anti-LPS) IgG in preventing or reducing sepsis in burns was carried out on 60 consecutive consenting adult burn victims with burns between 20 and 55 per cent of body surface area. Statistics failed to demonstrate a reduction in the mortality (P = 0.12) but did demonstrate a reduction in the incidence of burn wound infection (P = 0.0443), a fall in endotoxin levels in the first week (P = 0.041) and a rise in the anti-endotoxin levels after 5 units of anti-LPS plasma (P = 0.027). The logistics of carrying out such a trial are difficult but a larger patient population and modification of the original protocol might demonstrate a significant fall in mortality and morbidity. It was felt that some of the positive benefits of the high titre anti-LPS plasma might be due to factors other than the anti-LPS IgG.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7662126     DOI: 10.1016/0305-4179(94)00004-h

Source DB:  PubMed          Journal:  Burns        ISSN: 0305-4179            Impact factor:   2.744


  3 in total

Review 1.  The Chemistry of Lyophilized Blood Products.

Authors:  Joseph Fernandez-Moure; Nuzhat Maisha; Erin B Lavik; Jeremy W Cannon
Journal:  Bioconjug Chem       Date:  2018-06-13       Impact factor: 4.774

Review 2.  Selective digestive decontamination (SDD) as a tool in the management of bacterial translocation following major burns.

Authors:  Y A Aboelatta; A M Abd-Elsalam; A H Omar; M M Abdelaal; A M Farid
Journal:  Ann Burns Fire Disasters       Date:  2013-12-31

Review 3.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.